Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 6Breast Neoplasms, Male 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Uterine Cervical Neoplasms 1Teratoma 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Endodermal Sinus Tumor 1Central Nervous System Neoplasms 1Carcinoma, Embryonal 1

Interventions

Paclitaxel 11Carboplatin 9Taxes 8Gefitinib 7Radiotherapy 5Bevacizumab 5Radiation 4Erlotinib Hydrochloride 4Cisplatin 4Gemcitabine 3Etoposide 3Docetaxel 3Radiotherapy, Conformal 2Neoadjuvant Therapy 2veliparib 1vandetanib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1motesanib diphosphate 1Thalidomide 1TER 286 1Specimen Handling 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1MK 2206 1Ipilimumab 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma, Bronchiolo-Alveolar × pegfilgrastim × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡